Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study

Pablo Tolosa, Eva Ciruelos, Tomás Pascual et al.|Breast Cancer Research and Treatment|2026

Cited by 0